Cencora, Inc. (NYSE:COR) to Post Q4 2024 Earnings of $3.23 Per Share, Leerink Partnrs Forecasts

Cencora, Inc. (NYSE:COR) – Research analysts at Leerink Partnrs dropped their Q4 2024 earnings per share (EPS) estimates for Cencora in a research report issued on Monday, October 7th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $3.23 per share for the quarter, down from their previous forecast of $3.24. The consensus estimate for Cencora’s current full-year earnings is $13.63 per share. Leerink Partnrs also issued estimates for Cencora’s FY2027 earnings at $18.32 EPS and FY2028 earnings at $20.10 EPS.

COR has been the subject of several other research reports. Wells Fargo & Company boosted their price objective on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday, August 1st. Evercore ISI cut their price objective on Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a report on Tuesday. Leerink Partners cut their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a report on Monday. JPMorgan Chase & Co. upped their target price on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Finally, Bank of America reaffirmed a “neutral” rating and issued a $245.00 target price (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $259.44.

Cencora Stock Up 0.6 %

Shares of NYSE COR opened at $220.80 on Wednesday. Cencora has a 12 month low of $182.62 and a 12 month high of $247.66. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. The firm has a market capitalization of $44.04 billion, a price-to-earnings ratio of 24.16, a PEG ratio of 1.58 and a beta of 0.44. The business has a 50-day moving average of $234.25 and a 200-day moving average of $231.76.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The company had revenue of $74.20 billion during the quarter, compared to analyst estimates of $73.32 billion. During the same quarter in the previous year, the firm earned $2.92 earnings per share. Cencora’s revenue was up 10.8% on a year-over-year basis.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were paid a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend was Friday, August 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Insider Activity

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the sale, the insider now owns 19,980,000 shares of the company’s stock, valued at approximately $4,806,388,800. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Steven H. Collis sold 10,755 shares of the firm’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the sale, the chief executive officer now owns 285,088 shares of the company’s stock, valued at $63,323,746.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now directly owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,450,399 shares of company stock valued at $1,070,392,799. 15.80% of the stock is currently owned by company insiders.

Institutional Trading of Cencora

A number of institutional investors and hedge funds have recently added to or reduced their stakes in COR. Vanguard Group Inc. purchased a new stake in Cencora in the fourth quarter worth $4,212,508,000. Price T Rowe Associates Inc. MD purchased a new position in Cencora during the first quarter valued at $2,183,619,000. JPMorgan Chase & Co. purchased a new position in Cencora during the first quarter valued at $1,199,695,000. Boston Partners purchased a new position in Cencora during the first quarter valued at $1,001,269,000. Finally, Capital Research Global Investors purchased a new position in Cencora during the first quarter valued at $650,424,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.